A risk-prediction model that combines patients’ health history with clinical characteristics of their lung nodules may help physicians determine which will develop into cancer, according to the results of a study published in Cancer Prevention Research.

Using a predetermined formula, the ONS Board of Directors annually evaluates membership dues to ensure the levels will enable the Society to continue to provide ONS members with the high-quality products, services, and resources they need to transform care for patients with cancer. Based on the formula, the Board decided to maintain dues at the 2019 level for 2020.

Erdafitinib (Balversa™) is the first targeted therapy that the U.S. Food and Drug Administration approved for treatment of metastatic bladder cancer. 

As ONS advocates participate in the 2019 ONS Capitol Hill Days training and advocacy event in Washington, DC, from September 22–24, 2019, a recent Journal of Nursing Administration post about nursing influence in health policy is timely. It serves as a reminder that a nurse’s work in patient-centered care goes beyond the bedside or chairside. Nurses are educators, influencers, innovators, and sage guides for patients, policymakers, and the greater healthcare industry.

Pneumonitis is inflammation of the lung parenchyma; although rare, it can be fatal. Nishino et al. found that the overall incidence of pneumonitis with PD-1 inhibitor monotherapy was 2.7% for all-grade and 0.8% for grade 3 or higher pneumonitis. Naidoo et al. reported an approximate 5% incidence of all-grade pneumonitis, although the incidence of all-grade pneumonitis is higher with combination immunotherapy (up to 10%). The incidence is more common with higher grades in PD-1 inhibitors (versus PD-L1 inhibitors), but it occurs less often with anti-CTLA4 monoclonal antibodies. 

Dylan sat on the plastic chair with his elbows rested on his knees, staring blankly at the white tile floor in the clinic exam room. He was listening to me talk about the side effects of chemotherapy, but I could tell he had more on his mind. He lifted his head and touched his red baseball cap with his left hand.

“This is a lot to take in,” he said in a befuddled tone.

On September 17, 2019, the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada^TM) for patients with metastatic castration-sensitive prostate cancer. Apalutamide was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer.

Researchers are testing a new approach using an amphiphilic cancer vaccine to deliver CAR T-cell therapy to solid tumors, and the results of preclinical studies are promising, according to findings published in the journal Science.

On September 17, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the combination of pembrolizumab (Keytruda^®) plus lenvatinib (Lenvima^®) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation.

How are you taking care of yourself? It’s a question I’ve asked many team members, including leaders I have had the privilege of serving, over the course of my career. I’ve even added this question into certain candidate interviews to assess resiliency in individuals. And of course I ask it of myself often. That’s because it is my professional responsibility to ensure I am caring for myself. Provision 5 of the Code of Ethics for Nurses says, “The nurse owes the same duties to self as to others, including the responsibility to promote health and safety.”